1. Edition - July 2009
112.- Euro
2009. 460 Pages, Hardcover
ISBN-10: 0-470-22734-6
ISBN-13: 978-0-470-22734-3 - John Wiley & Sons






Sample Chapter

Short description
This book gathers present knowledge on the involvement of ABC transporters in drug transport and resistance. Bringing together updated information from an otherwise-scattered field of scientific literature, this resource helps researchers in pharmaceutical science in discovering drugs able to counteract multidrug resistance in diseases like cancer. It examines ABC transporters not only at the cancer cell, but also in other important physiological localizations. This book covers these topics as well as the pharmaceutical and medicinal modulation and inhibition of ABC transporters, helping pharmaceutical researchers discover drugs to counteract multidrug resistance in diseases like cancer.

From the contents
PREFACE.

CONTRIBUTORS.

INTRODUCTION: WHAT IS MULTIDRUG RESISTANCE (Jonathan A. Sheps and Victor Ling).

PART I ABC PROTEINS: AN OVERVIEW AND DESCRIPTION OF THE STRUCTURE, GENOME, NORMAL TISSUE EXPRESSION, PHYSIOLOGICAL ASPECT, AND MECHANISM OF ACTION.

1 The P-glycoprotein 170: Just a multidrug resistance protein or a protean molecule (Fabienne Grandjean-Forestier, Christophe Stenger, Jacques Robert, Mireille Verdier, and Marie-Hélène Ratinaud).

2 Multidrug resistance-associated protein (MRP/ABCC proteins) (Mylène Honorat, Charles Dumontet, and Lea Payen).

3 ABCG2: A new challenge in cancer drug resistance (Orsolya Polgar, Robert W. Robey, Kin Wah To, John Deeken, Patricia A. Fetsch, and Susan E. Bates).

PART II ABC PROTEINS AND ONCOLOGY: EXPRESSION, DETECTION, AND IMPLICATION OF ABC PROTEINS IN HEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS.

4 Expression, detection, and implication of ABC proteins in acute myeloblastic leukemia (Ollivier Legrand, Ruo-Ping Tang, and Jean-Pierre Marie).

5 ABC proteins and oncology: Expression, detection, and implication of ABC proteins in solid tumors (Jean François Bernaudin, Anne Fajac, Jocelyne Fleury-Feith, Khaldoun Kerrou, and Roger Lacave).

PART III ABC PROTEINS AND PATHOGENIC MICROORGANISMS.

6 ABC transporters and resistance to antibiotics (Serge Michalet and Marie-Geneviève Dijoux-Franca).

7 ABC proteins involved in protozoan parasite resistance (Bruno Pradines).

PART IV MULTIDRUG RESISTANCE (MDR) MODULATION THROUGH INHIBITION OF ABC TRANSPORTERS: DESIGN OF INHIBITORS AND MECHANISM OF ACTION.

8 Reversal agents for P-glycoprotein-mediated multidrug resistance (Hamid Morjani and Claudie Madoulet).

9 Reversal agents of multidrug resistance mediated by multidrug resistance-associated proteins (MRPs) (Ahcène Boumendjel, Anne Florin, and Jean Boutonnat).

10 Reversal agents for breast cancer resistance protein (BCRP)-mediated multidrug resistance (Jean Boutonnat, Anne Florin, and Ahcène Boumendjel).

11 Strategies to overcome drug resistance in acute and chronic leukemias (Eric Solary, Vincent Ribrag, and Stéphane de Botton).

12 Multidrug resistance reversal in solid tumors (Tatiana Bogush and Jacques Robert).

PART V BIOLOGICAL AND CLINICAL ASPECTS OF MULTIDRUG RESISTANCE: THE ROLE OF THE TRANSPORTERS AT THE MAIN PROTECTION BARRIERS (ABCB1, ABCC1, ABCC2, ABCG2) ON THE BIOAVAILABILITY OF MANY TYPES OF DRUGS AND MEDICATIONS.

13 ABC superfamily transporters at the human blood-brain barrier (Jean-Michel Scherrmann).

14 The role of ABC transporters at the intestinal barrier (Roos L. Oostendorp, Jos H. Beijnen, and Jan H.M. Schellens).

15 Genetic polymorphisms in ABC transporters (Leslie W. Chinn and Deanna L. Kroetz).

PERSPECTIVES.

INDEX.